GSK plc (NYSE:GSK) Shares Purchased by Horizon Kinetics Asset Management LLC

Horizon Kinetics Asset Management LLC increased its stake in shares of GSK plc (NYSE:GSK) by 4.4% during the 4th quarter, HoldingsChannel.com reports. The fund owned 39,865 shares of the pharmaceutical company’s stock after purchasing an additional 1,673 shares during the period. Horizon Kinetics Asset Management LLC’s holdings in GSK were worth $1,348,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. FMR LLC lifted its position in GSK by 8.3% during the 3rd quarter. FMR LLC now owns 29,008,928 shares of the pharmaceutical company’s stock worth $1,185,885,000 after acquiring an additional 2,224,345 shares in the last quarter. Fisher Asset Management LLC lifted its position in GSK by 4.9% during the 3rd quarter. Fisher Asset Management LLC now owns 18,576,930 shares of the pharmaceutical company’s stock worth $759,425,000 after acquiring an additional 870,449 shares in the last quarter. Clifford Capital Partners LLC lifted its position in GSK by 14.3% during the 3rd quarter. Clifford Capital Partners LLC now owns 409,669 shares of the pharmaceutical company’s stock worth $16,747,000 after acquiring an additional 51,378 shares in the last quarter. Cerity Partners LLC lifted its position in GSK by 61.8% during the 3rd quarter. Cerity Partners LLC now owns 433,628 shares of the pharmaceutical company’s stock worth $17,728,000 after acquiring an additional 165,556 shares in the last quarter. Finally, Natixis Advisors LLC lifted its position in GSK by 20.0% during the 3rd quarter. Natixis Advisors LLC now owns 500,495 shares of the pharmaceutical company’s stock worth $20,460,000 after acquiring an additional 83,433 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research firms recently commented on GSK. StockNews.com raised GSK from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 7th. Morgan Stanley started coverage on GSK in a report on Wednesday, February 12th. They set an “equal weight” rating on the stock. Seven investment analysts have rated the stock with a hold rating and four have issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

GSK Price Performance

Shares of NYSE GSK opened at $40.30 on Tuesday. GSK plc has a twelve month low of $31.72 and a twelve month high of $45.93. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The company has a market capitalization of $83.53 billion, a price-to-earnings ratio of 25.35, a price-to-earnings-growth ratio of 1.12 and a beta of 0.58. The business has a 50 day simple moving average of $36.18 and a 200-day simple moving average of $36.99.

GSK (NYSE:GSK) last issued its quarterly earnings results on Wednesday, February 5th. The pharmaceutical company reported $0.59 earnings per share for the quarter, beating analysts’ consensus estimates of $0.44 by $0.15. GSK had a return on equity of 48.59% and a net margin of 8.13%. As a group, equities research analysts expect that GSK plc will post 4.14 earnings per share for the current year.

GSK Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, April 10th. Stockholders of record on Friday, February 21st will be issued a $0.3932 dividend. This represents a $1.57 dividend on an annualized basis and a dividend yield of 3.90%. This is an increase from GSK’s previous quarterly dividend of $0.39. The ex-dividend date of this dividend is Friday, February 21st. GSK’s payout ratio is 98.74%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.